Boston Globe article “Massachusetts doctors going the startup route”

“Seeing patients is gratifying, but it’s on a different scale,” said Tweed-Kent, who earned a bachelor’s degree in chemical engineering from the University of Notre Dame. “As an entrepreneur, I’m potentially helping millions of patients.” – Ailis Tweed-Kent

Thank you to Jon Saltzman for a great piece on physician entrepreneurs. It is a joy and privilege to both care for and innovate for patients. What an honor to be featured alongside Shantanu and Sammy at Allurion and the many other physicians who have taken this path.

Click here to read the full article

Cocoon Biotech Announces CEO, Dr. Ailis Tweed-Kent, Named to Boston Business Journal’s “2017 Women to Watch in Science and Technology” List

BOSTON, Ma, February 16, 2017 – Cocoon Biotech, Inc., a biotechnology company focused on the development of osteoarthritis and other drug-delivery therapies based on its silk protein technology, has announced that Cocoon Founder and CEO, Ailis Tweed-Kent, M.D., has been named by the Boston Business Journal as one of the “2017 Women to Watch in Science and Technology” winners.

The journal has named Dr. Tweed-Kent as one of the ten recipients and according to the journal, “recognizes New England’s female technology and business leaders; the innovators who are helping to build new companies and drive established tech companies in new directions.” The honorees will be recognized today at the 14th Annual Women to Watch Awards Breakfast in Boston.

“I am honored, humbled and thankful to be named as a leader in this field of incredibly bright women who are each committed to making important advances in their respective areas of science and technology,” stated Dr. Tweed-Kent. “My hope is that the important work that we are doing at Cocoon Biotech will ultimately improve the lives of thousands of patients worldwide who are suffering from osteoarthritis.”

About Cocoon Biotech, Inc.

Cocoon Biotech was founded in 2013 to bring treatments for arthritis and other debilitating diseases to market. Cocoon Biotech’s platform technology is a biocompatible silk protein that can be loaded with small molecule or protein therapeutics and injected into joints to provide effective, long-lasting pain relief and potentially delay the progression of disease. This platform will leverage several unique properties of the silk protein fibroin, including strength and biocompatibility. For more information, please visit www.cocoonbiotech.com.

Contact:

Jennifer Williams

Cook Williams Communications, Inc.

650-315-3538

jennifer@cwcomm.org

Cocoon Biotech Announces Partnership with Camargo Pharmaceutical Services for Development Programs

Cambridge, MA  February 2, 2017 – Cocoon Biotech, Inc. (“Cocoon” or the “Company”), is a biotechnology company focused on utilizing its silk protein-based drug delivery technology for the development of formulations to treat osteoarthritis and other conditions for which many patients find existing treatments to be unsatisfactory.  Cocoon announced today that it has entered into service agreements with Camargo Pharmaceutical Services, LLC (“Camargo”) to provide end-to-end regulatory consulting and strategic development services for Cocoon’s pipeline of products initially developed for the treatment of osteoarthritis. The first joint program will involve biocompatible silk fibroin loaded with a small molecule therapeutic, and will include pre-Investigational New Drug (pre-IND) meeting planning and preparations through to New Drug Application (NDA) submissions.

Camargo is a highly experienced global strategist specializing in drug and combination device product development and approval utilizing the regulatory pathway provided for in Section 505(b)(2) of the US Federal Food, Drug, and Cosmetic Act. Over the last decade, Camargo has established an unrivaled track record with 505(b)(2) IND and NDA preparations and submissions, including participation in more than 1100 FDA meetings and more than 200 FDA NDA and ANDA approvals.

“We are pleased to be partnering with Camargo, as they will be an important part of the team which will help execute our pre-IND and overall regulatory strategy in an effort to expedite our products into the clinic and ultimately into the hands of physicians who can help the many osteoarthritis patients in need of more effective medicines,” stated Ailis Tweed-Kent, M.D., founder and chief executive officer of Cocoon Biotech. “We believe that the vast experience that Camargo has in navigating regulatory agencies worldwide will be very beneficial to Cocoon both in the near-term and in years to come.”

“Our goal at Camargo is to guide our clients with the most cost- and time-effective strategy to navigate the 505(b)(2) regulatory pathway, while driving commercial success for our client-partners,” said Ken Phelps, President and CEO of Camargo Pharmaceutical Services. “Cocoon’s vision of enabling healthy, productive lives for patients worldwide by utilizing silk protein technology excites all of us at Camargo.”

About Silk Fibroin Technology

Cocoon Biotech’s platform technology is biocompatible silk fibroin leveraged as a drug delivery material for osteoarthritis and other unmet medical needs. Silk protein has been shown to be biocompatible and biodegradable in humans, and can be formulated to release active small molecule or biologic drugs locally over many months. Our lead program is a silk fibroin hydrogel loaded with a small molecule drug that aims to provide long-term relief of pain and inflammation when injected into the joint of patients living with osteoarthritis. This lead product is targeted to provide significant safety and/or efficacy advantages over existing oral or intra-articularly delivered treatments for osteoarthritis.

About Cocoon Biotech Inc.

Cocoon Biotech was founded in 2013 to bring treatments for arthritis and other debilitating diseases to market. Cocoon Biotech’s platform technology is biocompatible silk protein that can be loaded with small molecule or protein therapeutics and injected into joints to provide effective, long-lasting pain relief and potentially delay the progression of disease. This platform will leverage several unique properties of the silk protein fibroin, including biocompatibility, stability, ease of manufacturing, and the ability to form injectable hydrogels containing high drug loads. For more information, please visit www.cocoonbiotech.com.

 

About Camargo Pharmaceutical Services

Camargo Pharmaceutical Services is the most experienced team of experts providing comprehensive drug development services specialized for the 505(b)(2) approval pathway and global equivalent processes. By assessing the scientific, medical, regulatory and commercial viability of product development opportunities, Camargo systematically builds and executes robust development plans that align with business strategies and ensure Agency buy-in every step of the way. With alignment through pre-Investigational New Drug (pre-IND) meeting planning and preparations, Camargo maintains and ensures consistency throughout the drug development program, which increases the likelihood of NDA and future market success. Routinely holding three to six pre-IND meetings a month, Camargo works with product developers across more than 25 countries. To learn more about Camargo Pharmaceutical Services, please visit http://camargopharma.com.

 

 

 

Contact Information for Cocoon Biotech Inc.:

Jennifer Williams

Cook Williams Communications, Inc.

650-315-3538

jennifer@cwcomm.org

 

 

Contact Information for Camargo Pharmaceutical Services

Jennifer King

services@camargopharma.com

http://camargopharma.com

1 (513) 561-3329 | 1 (888) 451-5708

 

 

Cocoon Biotech to Explore New Treatments for Joint Disease using Silk Biomaterial Platform Developed at Tufts University

Cocoon Biotech to Explore New Treatments for Joint Disease using Silk Biomaterial Platform Developed at Tufts University

BOSTON (November 4th, 2014) — Cocoon Biotech today announced that it has entered into exclusive option and sponsored research agreements with Tufts University to explore the commercialization of new treatments for joint disease and arthritis using silk protein polymers.  The silk biomaterial platform was developed in the laboratory of David L. Kaplan, Ph.D, Stern Family professor and chair of biomedical engineering at Tufts School of Engineering, and spans many biomedical and industrial applications.

Cocoon Biotech is in the formative stages of developing products to treat osteoarthritis, a crippling disease affecting 27million Americans and over 150 million people worldwide.  Existing approaches to treat arthritis, especially to the knee joint, include frequent steroid injections and eventual surgical knee replacement that directly cost the US healthcare system over $100 billion annually according to the Centers for Disease Control (Yelen, et al. 2007).

“Silk is a natural protein with outstanding lubrication features for the joint.  Silk has been used in sutures and other implants for many decades demonstrating a favorable safety profile and has received prior FDA approval for certain medical devices.  Silk can also be engineered to biodegrade at desired rates and release a variety of medications locally into the joint space to facilitate tissue healing,” said David Kaplan.

Joint lubrication is a newer therapeutic option for osteoarthritis, in which a biomaterial is injected into damaged joints to reduce the friction between cartilage surfaces and relieve symptoms such as pain and inflammation.

“Cocoon Biotech joins a growing number of promising silk technology based ventures spun out of Tufts,” said Erik Halvorsen, ‎senior director, Tufts Tech Transfer & Industry Collaboration (TTIC).  “We are thrilled to work with Cocoon to enable the development of such innovative treatment solutions utilizing the silk biomaterial platform for the benefit of the public.”

Dr. Ailis Tweed-Kent, founder and CEO of Cocoon Biotech added, “Our collaboration with Tufts will help bring needed relief to those suffering the effects of osteoarthritis.  As a physician, I am both heartened and resolved that Cocoon is now poised to provide a cost-effective solution to this huge problem facing patients.”

About Cocoon Biotech:  Cocoon Biotech, Inc., Boston, MA was founded in 2013 to bring treatments for arthritis and other debilitating diseases to market.  The company has completed seed financing and is testing prototype products in the laboratory.

More at: CocoonBiotech.com

About Tufts Tech Transfer & Industry Collaboration (TTIC): The core mission of TTIC is to identify, evaluate, patent, and commercialize innovative Tufts inventions and technologies and to support research, innovation, entrepreneurship, and translation of Tufts technologies.  More at: TechTransfer.Tufts.edu